Pharmazen Limited v Anagenix IP Limited

Link copied
Case Copied 32 min read

IN THE HIGH COURT OF NEW ZEALAND WELLINGTON REGISTRY

I TE KŌTI MATUA O AOTEAROA TE WHANGANUI-A-TARA ROHE

CIV-2018-485-741

[2019] NZHC 1520

BETWEEN

PHARMAZEN LIMITED

Appellant

AND

ANAGENIX IP LIMITED

Respondent

Hearing: 25 March 2019

Appearances:

J V Ormsby and T M Ritchie for the Appellant S Wheeldon for the Respondent

Judgment:

1 July 2019


JUDGMENT OF CULL J


TABLE OF CONTENTS

Background  7

The Commissioner’s decision  9

Approach to appeal  12

Preliminary issue of evidence  18

Legal framework  22

Issues  27

Issue One: whether the goods are similar  28

Issue Two: whether the trade marks are similar  40

Visual comparison  43

Aural Comparison  49

Conceptual/descriptive comparison  54

Discussion  58

Issue Three: whether the trade mark would be likely to deceive or confuse  64

Result  80

[1]    Pharmazen Limited’s (Pharmazen) application to register its trademark, ActiPhen, was declined by the Assistant Commissioner of Trade Marks (the Commissioner).1 Pharmazen appeals the Commissioner’s decision (the Decision).

1      Pharmazen Limited v Anagenix IP Limited [2018] NZIPOTM 27.

PHARMAZEN LIMITED v ANAGENIX IP LIMITED [2019] NZHC 1520 [1 July 2019]

[2]    The Commissioner found that the ActiPhen trademark is similar to Anagenix IP Limited’s (Anagenix) mark, ACTAZIN,2 is in respect of similar goods,3 and that it is likely a significant number of persons in the relevant market would be deceived or confused by Pharmazen’s use of the mark under s 25(1)(b) of the Trade Marks Act 2002 (the Act).4

[3]    Although Anagenix was successful under s 25(1)(b) of the Act, the Commissioner went on to find Anagenix failed in its other grounds of opposition under s 17(1) of the Act. Section 17(1)(a) requires that the use of the applied-for trade mark must not be likely to deceive or confuse, and s 17(1)(b) requires that the use of the applied-for trade mark must not be contrary to the Fair Trading Act 1986 or other New Zealand law for being misleading or deceptive.

[4]    Pharmazen appeals the Decision under s 170 of the Act. Pharmazen submits that the Commissioner’s Decision relating to s 25(1)(b) is wrong and inconsistent with other findings made by the Commissioner: the same conclusions which led Anagenix to  fail in respect of s 17(1)(a)  must  necessarily mean  that Anagenix  fails under     s 25(1)(b).

[5]Accordingly, Pharmazen submits:

(a)the Commissioner erred in fact and law in finding that the goods are similar;

(b)the Commissioner erred in fact and law in finding that the trade marks are similar; and

(c)the Commissioner erred in fact and law in finding that a significant number of persons in New Zealand would be deceived or confused by Pharmazen’s use of the ActiPhen mark.


2 At [65].

3 At [53].

4 At [69].

[6]    Anagenix submits the Commissioner made no error in fact or in law: the goods are similar and the marks are similar, such that Pharmazen’s use of the ActiPhen mark would be likely to deceive or confuse a significant number of people.

Background

[7]    On 4 May 2016, Pharmazen lodged an application to register the “ActiPhen” trade…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Pharmazen Limited v Anagenix IP Limited and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2019] NZHC 1520
Decision Date

CaseChat Overview and Summary

Pharmazen Limited (Pharmazen) appealed against the Assistant Commissioner of Trade Marks' (Commissioner) decision to decline its application to register ActiPhen as a trademark. Pharmazen argued that the Commissioner's decision was inconsistent because, while Anagenix IP Limited (Anagenix) was successful under s 25(1)(b) of the Trade Marks Act 2002 (the Act), it failed in other grounds of opposition under s 17(1) of the Act. The High Court considered three issues: whether the goods are similar, whether the trademarks are similar, and whether the use of the trademark would be likely to deceive or confuse. On the first issue, the Court found that there could be no real doubt that the parties' respective goods were similar. On the second issue, the Court found that the trademarks were similar both visually and aurally. On the third issue, the Court found that the Commissioner was correct in upholding Anagenix's opposition that a significant number of persons in the relevant market would be likely to be caused to wonder whether the ActiPhen mark was the same as or related to the ACTAZIN mark. The appeal was dismissed.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established